Drawdown of Tranche 2 under the Convertible Note Facility
Filed with ASX · · 2 pages · English
Paradigm Biopharmaceuticals Ltd. (ASX: PAR) (“Paradigm” or “the Company”) a late-stage drug development company focused on delivering new therapies to address unmet medical needs, advises that it has completed the drawdown of Tranche 2, valued at US$5 million (approximately A$7.64 million), under its US$27 million (A$41.2 million) Convertible Note Facility with Obsidian Global Partners, LLC. The d
Paradigm Biopharmaceuticals Ltd. on 6ix
In the deck
Earlier from Paradigm Biopharmaceuticals
- September 2025 Quarterly Activities Report & Appendix 4C
- Phase 3 Knee OA Trial Recruiting and Dosing in AUS & US
- Appendix 4E and 2025 Annual Report
- June 2025 Quarterly Activities Report & Appendix 4C
- Paradigm Secures US$27M to Advance Phase 3 OA Trial
Later from Paradigm Biopharmaceuticals
- Phase 3 Knee OA Trial Recruitment Update
- iPPS Phase 2 Biomarker Results Published in Leading Journal
- December 2025 Quarterly Activities Report & Appendix 4C
- Oral OA Animal Therapy Progresses via AVet Deal
- Published Canine Study Strengthens iPPS Phase 3 Rationale
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals